Virtual Library
Start Your Search
D. Pandey
Author of
-
+
P1.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 233)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P1.04-080 - miR-326 Is Down-Regulated in Non-Small Cell Lung Cancer and Targets NFIB, a Lung Developmental Gene: A Pilot Study (ID 1326)
09:30 - 09:30 | Author(s): D. Pandey
- Abstract
Background:
Lung cancer is the leading cause of cancer mortality worldwide. Non-small cell lung cancer (NSCLC) is the most common subtype, accounting for about 80% of all lung cancers. miRNAs are small RNAs of 21-24 nucleotides in length, which play major role in cell proliferation and differentiation and their differential expression is known to be associated with various cancers including lung cancer. Role of miR-326 has been previously studied as a marker of bone metastasis in lung cancer. Moreover, we have previously shown that miR-326 plays a critical role in the epithelial to mesenchymal transition (EMT) by targeting transforming growth factor (TGF)-β1 and other members of TGF-β signaling pathway. The aim of present study is to check the expression and correlation of miR-326 and lung epithelial developmental gene nuclear factor IB (NFIB) in non-small cell lung cancer tissue samples as cancer metastasis is accompanied by EMT.
Methods:
We have examined eight pathologically confirmed non-small cell lung cancer cases. All patients were men and smokers with age ranged from 29 to 74 years (mean 54.6 years). Surgical resection was performed in all the cases which were either stage II or III. Histopathologically, 4 cases were squamous cell carcinomas, 3 were adenocarcinomas including one case of invasive mucinous carcinoma and one case was low grade mucoepidermoid carcinoma. RNA was isolated from fresh frozen tissue to check for miR-326 and NFIB levels by real time PCR. Protein expression was checked by immunohistochemistry (NFIB; 1:200; Abcam)) and in-situ hybridization (miR-326; Exiqon). Adjoining lung tissue served as normal control in each case.
Results:
Expression of both miR-326 and NFIB was found to be down regulated in non-small cell lung cancer tissue at both RNA and protein level (Fig 1A-C). Our in silico experiments identified a target site of miR-326 at the 3’UTR of NFIB gene; presumably it stabilizes the transcripts of NFIB (Fig 1D). Figure 1
Conclusion:
Our preliminary data suggests that miR-326 stabilizes the transcripts of NFIB in normal epithelial cells and maintain epithelial cell integrity. Dysregulation of miR-326 and NFIB in non-small cell lung cancer indicate that miR-326 and NFIB work synergistically and may contribute to the development of non-small cell lung cancer.
-
+
P2.03 - Poster Session/ Treatment of Locoregional Disease – NSCLC (ID 213)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Locoregional Disease – NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.03-008 - Surgery for Primary Lung Tumors with Histology Other than Non-Small Cell Lung Cancer: A Single Center Experience (ID 1306)
09:30 - 09:30 | Author(s): D. Pandey
- Abstract
Background:
Primary lung tumors with histology other than small cell and non-small cell carcinoma are uncommon, and generally have a better prognosis and differing criteria of resectability. We present our experience of surgery in such tumors over the last three years at a tertiary cancer center in north India.
Methods:
This is an analysis of a prospective database of patients with primary lung tumors undergoing surgery in a three-year period between May 2012 and April 2015 at the Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi. We included the group of patients with histology other than non-small cell lung cancer (NSCLC). Details concerning the clinical presentation, preoperative therapy, operative procedure, postoperative complications and outcome were retrieved from the database.
Results:
Between May 2012 and April 2015, out of the 101 patients who underwent surgery for primary lung neoplasm, twenty eight (28) patients had histology other than NSCLC. There were 19 males and 9 females, with a median age of 36 (range 6 to 64). They included 18 patients with carcinoid tumor, 3 with mucoepidermoid tumor, 4 with adenoid cystic carcinomas, 2 with myofibroblastic tumor, and 1 with clear cell tumor. Four patients had been previously treated presumptively for pulmonary tuberculosis, and two had received chemotherapy elsewhere before presenting to us. Two patients had prior bronchoscopic debulking. The surgical procedures included lobectomy in 8, bilobectomy in 8, pneumonectomy in 10, and pneumonectomy with carinal resection in 2 patients. Bronchoplastic procedures or sleeve resections were performed in 5 patients. All these surgeries were performed using muscle-sparing thoracotomy approach, except in two patients who underwent left pneumonectomy with carinal resection and reconstruction using median sternotomy approach and cardiopulmonary bypass. Postoperative morbidity was observed in 5 patients (prolonged air leak in 2patients, postoperative lung collapse, pneumonia, and empyema in one patient each). There was one postoperative mortality; this patient had mucoepidermoid carcinoma of the left main bronchus for which he underwent left pneumonectomy with carinal resection under cardiopulmonary bypass through median sternotomy approach. He was re-explored for a pericardial bleed on the first postoperative day, subsequently developed postoperative pneumonia of the solitary lung, and succumbed on 9th]postoperative day. Although the follow-up period is short, there has been no recurrence so far; and all patients are surviving without evidence of disease, except the one patient who died due to postoperative complications.
Conclusion:
Patients with carcinoid tumor, minor salivary gland neoplasm, or other unusual histologies of the lung usually have a better prognosis than those with non-small cell carcinoma. Aggressive surgical approaches should be pursued in such tumors, even in face of advanced local disease that would preclude resection in NSCLC.
